Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762

Dec 23, 2025 | Press Releases

Nonclinical protocol study design accepted by FDA Study to commence in First Quarter 2026King of Prussia, Pennsylvania–(Newsfile Corp. – December 23, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...

Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762

Nov 25, 2025 | Press Releases

King of Prussia, Pennsylvania–(Newsfile Corp. – November 25, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology...

Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress

Nov 17, 2025 | Press Releases

Presenting INTASYL siRNA Drug TechnologyKing of Prussia, Pennsylvania–(Newsfile Corp. – November 17, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary...

Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 13, 2025 | Press Releases

Clinical Trial has Advanced to Fifth and Final Cohort at Maximum Dose of INSTASYL PH-762 in Skin Cancer Trial Positive Pathology Results at Maximum Dose: 100% Tumor Clearance (Complete Response) in One Patient, Greater than 90% (Near Complete Response) in Second...

Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762

Nov 7, 2025 | Press Releases

Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)King of Prussia, Pennsylvania–(Newsfile Corp. – November 7, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...